VPVladislav E. Pustynnikov

Vladislav E. Pustynnikov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Vladislav E. Pustynnikov has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Immunohistochemical analysis of Klotho protein expression in the cerebral cortex of aging rats with diabetes mellitus under pharmacological correction

    by Alexey V. Smirnov, Смирнов Алексей Владимирович, Aislu I. Dzhukeeva, Джукеева Айслу Ильнуровна, Vladislav E. Pustynnikov, Пустынников Владислав Эдуардович, Dmitry A. Bakulin, Бакулин Дмитрий Александрович, Yulia I. Velikorodnaya, Великородная Юлия Ивановна, et al.

    Diabetes mellitus leads to the development of vascular and cognitive impairment, which collectively leads to diabetic encephalopathy. Klotho protein (K), a critical regulator of aging and cognitive health, is considered a key link in the pathogenesis of diabetic encephalopathy. GABA derivatives are of particular interest in the search for neuroprotective strategies; however, their effect on Klotho expression in the context of diabetic brain damage remains poorly understood. The aim of the study: To study Klotho protein expression in the cerebral cortex of aging rats with diabetes mellitus and its pharmacological correction. Research methodology: A 6-month model of streptozotocin-induced diabetes mellitus was conducted in 36 Wistar albino rats (12 months old). Six months after the modeling of diabetes mellitus, the animals received succicard (50 mg/kg/day) or aminalon (1000 mg/kg/day) for one month. The area of immunoreactive material (anti-Klotho antibodies) in the retrosplenial cortex was measured using morphometry and Image J software. Statistical data processing was performed using ANOVA. The results of the research: Klotho protein expression in neurons and neuropil of the retrosplenial cortex was lower in animals with severe neurodegenerative disorders associated with diabetes mellitus than in healthy animals. These data suggest that Klotho protein deficiency plays a significant role in the development of diabetic encephalopathy in aging rats. In aging animals treated with the test compounds aminalon and succicard, Klotho protein expression was higher than in untreated rats. Conclusions: Analysis of pathological changes and Klotho protein expression in the cerebral cortex of aging rats with experimental streptozotocin-induced diabetes mellitus revealed a marked decrease in Klotho protein expression, even to the point of being absent, in the motor, primary somatosensory, and auditory cortex, as well as a less pronounced decrease in expression in the retrosplenial cortex. Pharmacological correction with aminalon and succicard demonstrated restoration of Klotho protein expression in the perikarya of neurons in the retrosplenial cortex. The results of the study suggest that the compounds studied may be effective in the treatment of diabetic encephalopathy.

  • Open Access

    Features of GFAP expression in hippocampus of mature rats during modeling of type 1 diabetes mellitus and pharmacological correction

    by Alexey V. Smirnov, Ivan N. Tyurenkov, Vladislav E. Pustynnikov, Yulia I. Velikorodnaya, Andrey D. Petrov

    Investigation of the expression of glial fibrillary acidic protein (GFAP), a key marker of the functional state of astrocytes, in experimental modeling of diabetes mellitus (DM) is relevant due to the high incidence of diabetic encephalopathy in elderly patients with DM and the limited data on pathogenetic approaches to its therapy. Materials and methods: Using a model of type 1 DM induced by streptozotocin in 50 Wistar rats (aged 12 months), the effects of a 30-day course of aminalon (1000 mg/kg/day), succicard (50 mg/kg/day), and mefargin (20 mg/kg/day) were studied after 6 months of persistent hyperglycemia. GFAP expression in the hippocampus was assessed immunohistochemically followed by morphometry in ImageJ software and statistical analysis using ANOVA. Results and discussion: In the group of untreated diabetic animals, a significant decrease in the relative area of GFAP expression in hippocampal astrocytes was recorded compared to the intact control. Treatment with aminalon resulted in a larger area of immunoreactive material (IRM) in hippocampal neurons compared to diabetic animals. Animals receiving succicard also showed a larger area of IRM in hippocampal neurons compared to untreated diabetic animals. In diabetic animals treated with mefargin, a trend toward increased IRM was noted compared to material from untreated animals. Conclusion: Experimental DM leads to decreased GFAP expression in the hippocampus, indicating impaired astrocytic homeostasis and the involvement of glial cells in mechanisms of neuroinflammation in diabetic encephalopathy. GABA and its derivatives exert effects on astrocytes and promote the restoration of GFAP expression levels. The obtained results substantiate the promise of further investigation of GABA derivatives as agents for neuroprotection in cognitive disorders of diabetic origin.

  • Open Access

    Correction by neuroglutam and succicard of age-associated impairments in accelerated aging in rats with diabetes

    by Alexandr A. Pokhlebin, Nikita S. Bolokhov, Gennady Yu Balakin, Vladislav E. Pustynnikov, Olga S. Vasilyeva, Ivan N. Tyurenkov

    Introduction: The study aimed to investigate the impact of a long-term diabetic state on the development of accelerated aging and to evaluate the efficacy of therapy with metformin, neuroglutam, and succicard in correcting associated metabolic, behavioral, and molecular impairments. Materials and Methods: A diabetes model was induced in rats by combined administration of streptozotocin (50 mg/kg) and nicotinamide (110 mg/kg). The total number of animals involved in the experiment was 50 individuals (25 males, 25 females). The animals were divided into 5 groups: intact, control (diabetic), and groups receiving a 4-week course of metformin (400 mg/kg), neuroglutam (26 mg/kg), or succicard (50 mg/kg). A comprehensive assessment was performed, including behavioral tests (open field, elevated cross maze, novel object recognition, forced swimming with a load, rotarod), metabolic status (oral glucose tolerance test, OGTT), and Klotho protein levels (ELISA). Results: Diabetes induced anxiety-like behavior, cognitive decline, impaired motor coordination, and a significant decrease in Klotho protein levels. Therapy with metformin and succicardsignificantly increased Klotho protein levels and improved metabolic parameters. Neuroglutam exhibited pronounced nootropic and antidepressant-like effects. All drugs demonstrated differential effects on various aspects of behavioral activity. Conclusion: The study demonstrates the potential of using metformin (400 mg/kg), neuroglutam (26 mg/kg), and succicard (50 mg/kg) to correct the manifestations of accelerated aging in diabetic rats with daily administration for 4 weeks. Metformin and succicard showed the most pronounced geroprotective potential. The results justify further investigation of combination therapy for correcting age-associated impairments.

  • Open Access

    Immunohistochemical analysis of Klotho protein expression in the brain of aging rats with diabetes mellitus under pharmacological correction

    by Alexey V. Smirnov, Aislu I. Dzhukeeva, Ivan N. Tyurenkov, Maria R. Ekova, Vladislav E. Pustynnikov, Dmitry A. Bakulin, Nikita S. Bolokhov, Alexander A. Pokhlebin, Julia I. Velikorodnaya, Alexander I. Krayushkin, et al.

    The Klotho protein is one of the key regulators of aging and metabolism in the brain of aging rats. The relevance of the work is due to the high prevalence of diabetic encephalopathy in elderly people with diabetes and the lack of knowledge of the mechanisms of its correction. Materials and methods. Type 1 diabetes was modeled on 36 Wistar rats at the age of 12 months by administration of streptozotocin. After 6 months of hyperglycemia, the animals received aminalon (1000 mg/kg/day) or succicard (50 mg/kg /day) for 30 days. The expression of Klotho protein in the retrosplenic cortex, hippocampus, thalamus, and hypothalamus was evaluated by immunohistochemistry. Quantitative analysis was performed using the ImageJ program, statistical significance was determined using ANOVA. Results and discussion. In rats with DM without treatment, lower levels of IRM expression using polyclonal antibodies against the Klotho protein were detected in the retrosplenic cortex, hippocampus, thalamus and hypothalamus, which, in comparison with intact animals, indicates a possible dysfunction of neuronal metabolism and a decrease in the protective activity of the Klotho protein in conditions of diabetic neurodegeneration. During aminalon therapy, the expression level of Klotho was higher than in animals without therapy. During Succicard therapy, Klotho levels exceeded those of the untreated group, but were inferior to aminalon. Conclusions. When modeling diabetes mellitus (DM), a decrease in the expression of immunoreactive material was noted when using antibodies against the Klotho protein in the retrosplenic cortex, hippocampus, thalamus and hypothalamus of rats, which indicates the appearance of signs of premature aging in brain structures against the background of triggering neuroinflammation processes, which contributes to the development of diabetic enephalopathy. During aminalon therapy, the expression level of the Klotho protein increased significantly. Treatment with succicard diabetes contributed to a less pronounced increase in the level of Klotho protein expression compared with aminalon. The results of the study confirm the prospects of searching for a number of GABA derivatives in diabetes, taking into account metabolic disorders in the Klotho/FGF 23 signaling pathway (fibroblast growth factor 23, fibroblast growth factor 23) in key cerebral structures.

  • Open Access

    Psychotropic activity evaluation of bromantane — N-(camphan-2-yl)anilines new structural analogues in in vivo tests

    by A. A. Vernigora, L. L. Brunilina, A. V. Kazhberov, N. S. Bolokhov, A. A. Pokhlebin, A. A. Sokolova, V. E. Pustynnikov, I. N. Tyurenkov, I. A. Novakov, V. I. Krasnov, et al.

    The aim of the work was the synthesis of bromantane - N-(camphan-2-yl)anilines new structural analogues and the study of their psychotropic properties.Materials and methods. The synthesized compounds were identified using the NMR spectroscopy. The purity of the compounds was confirmed by a GC-MS analysis. Psychotropic properties of N-(camphan-2-yl)anilines were studied in the experiments on the Wistar rats aged 18-20 weeks, the mice (12 weeks old) obtained from the “Stolbovaya” nursery using the following tests: the “Open Field”, the “Elevated Plus Maze”, the “Novel Object Recognition”, the “Vogel Conflict”, the “Tail Suspension”, the “Tightrope suspension”, the “Extrapolation” test.Results. A series of new camphor aromatic amines, structural analogues of bromantane, were obtained and their psychotropic effects were evaluated by in vivo biological studies. Based on the results, it was possible to identify a leader compound, i.e. (1R,2R,4R)-1,7,7-trimethyl-N-(4-ethylphenyl)bicyclo[2.2.1.1]heptan-2-amine (4e), which had a pronounced anxiolytic effect. Substance 4f showed cognitive properties in the “Novel Object Recognition” and the “Extrapolation” tests. The fact was established by the indices of the time of learning a novel object and the time of diving.Conclusion. The obtained data testify to the prospect of searching for substances with a psychotropic action in the range of aromatic camphor amines. Substance 4f, which deserves an in-depth study of the spectrum and mechanism of its psychotropic action, should be singled out separately.


  • Open Access

    Cerebroprotective effect of sitagliptin and aminoguanidine combination in disorders of cerebral circulation

    by D. V. Kurkin, D. A. Bakulin, E. I. Morkovin, Yu. V. Gorbunova, A. V. Strygin, T. M. Andriashvili, A. A. Sokolova, N. S. Bolokhov, V. E. Pustynnikov, E. A. Fomichev, et al.

    The aim of the study was to evaluate a cerebroprotective activity of the sitagliptin and aminoguanidine combination in rats with an acute and chronic cerebral circulation insufficiency, as well as with a traumatic brain injury.Materials and methods. The study was carried out on male Wistar rats in 3 stages using, respectively, a model of a chronic pathology: a chronic cerebral circulation insufficiency (CCCI), as well as 2 models of the acute brain injury (BI): an acute cerebral circulation insufficiency (ACCI), and a traumatic brain injury (TBI). А CCCI was modeled by a bilateral stenosis of the common carotid arteries (by 50%), a model of a hemorrhagic stroke caused by an intracerebral injection of the autologous blood was used as a stroke, a TBI was modeled by a mechanical damage to the brain tissue. To assess the pathology course severity, the following tests were used: Adhesion test, Open field, Morris water maze test, as well as Garcia and Combs&D’Alecy scales. In the animals with an acute damage to the brain at the end of the experiment, the severity of edema of the affected hemisphere was also determined. The treatment was with sitagliptin (10 mg/kg), aminoguanidine (25 mg/kg), or a combination thereof. The obtained data were subjected to the statistical processing.Results. In the course of the study, it was found out that the administration of a sitagliptin and aminoguanidine combination, unlike each of the components, had a cerebroprotective effect in the animals with a chronic or acute damage to the brain, reducing the severity of psychoneurological (cognitive and sensory-motor) disorders, as well as the brain edema.Conclusion. Aminoguanidine, as an iNOS blocker, enhances the action of sitagliptin, preventing the brain edema development and reducing the neurological deficit severity (the severity of cognitive and sensory-motor impairments) in the animals with an acute and chronic cerebral circulation insufficiency.

  • Open Access

    HYPOGLYCEMIC EFFECT OF SITAGLIPTIN AND AMINOGUANIDINE COMBINATION IN EXPERIMENTAL DIABETES MELLITUS

    by D. V. Kurkin, D. A. Bakulin, E. I. Morkovin, Yu. V. Gorbunova, A. V. Strygin, T. M. Andriashvili, A. A. Sokolova, N. S. Bolokhov, V. E. Pustynnikov, E. A. Fomichev

    The aim of the work was to determine the antidiabetic effect of a sitagliptin and aminoguanidine combination in rats with experimental diabetes mellitus.Materials and methods. The study was carried out on male Wistar rats and C57BL/KsJ-db/db mice. According to the models used, it was divided into 4 series, in which alloxan, steroid-induced (dexamethasone) and streptozotocin-nicotinamide-induced diabetes mellitus (DM) were formed, respectively, in rats, and in the 4 series, obese C57BL/KsJ-db/db mice were used. In the 1 and 2 series, the treatment was started prophylactically – 3 h after the alloxan administration and simultaneously with the dexamethasone administration, in the 3rd and 4th series, the treatment was carried out after the pathology had developed – 7 days after the streptozotocin with nicotinamide administration, and in the obese mice – immediately after their distribution according to the groups. The treatment was carried out with sitagliptin (10 mg/kg), aminoguanidine (25 mg/kg), or a combination thereof. The treatment was continued till the end of the experiment, which was completed with an oral glucose tolerance test (OGTT) after 4 h of fasting. The obtained data were subjected to statistical processing.Results. In the course of the experiments, it was found out that the prophylactic administration of a sitagliptin and aminoguanidine combination, unlike each of the components, prevented the development of alloxan DM. More effectively than the administration of sitagliptin alone, it reduced the severity of steroid-induced DM, which was expressed in a significantly lower level of fasting glycemia (after 4 h of fasting) and postprandial glycemia (during OGTT). Under the conditions of streptozotocin-nicotinamide-induced DM, the studied combination slowed down the progression of the pathology, and in the obese mice, the course therapeutic administration of sitagliptin and its combination reduced the severity of carbohydrate metabolism disorders (fasting glycemia) and increased the rate of glucose utilization.Conclusion. As an iNOS blocker, aminoguanidine enhances the antidiabetic effect of sitagliptin, preventing the development of alloxan diabetes and reducing the severity of steroid-induced DM when administered prophylactically. When administered therapeutically, it reduces the severity of streptozotocin-nicotinamide-induced DM in rats and type 2 DM in mice with a predisposition to obesity.


  • Open Access

    Effect of benzoyl taurine dipotassium salt on coagulation, hemostasis and vascular activity in the microvasculature of the brain in violation of cerebral circulation

    by V. E. Pustynnikov, S. S. Tsaruk, E. A. Fomichev, E. A. Miloserdova, D. V. Kurkin, D. A. Bakulin, T. M. Andriashvili, A. A. Sokolova, N. V. Atapina, А. К. Брель, et al.

    Cerebral circulation disorders (CCD) are one of the most common causes of mortality and disability in the population. Improving the microcirculation of brain tissue is one of the main directions in the treatment and prevention of CCD.Aim of the study was to evaluate the effect of a new derivative of hydroxybenzoic (salicylic) acid on neurological deficit, hemostasis and functional state of arterial pial vessels in the study of prostacyclin-synthetic activity and evaluation of NOmediated endothelial dysfunction in rats under experimental CCD conditions. Material and methods. The experiment was carried out on 50 Wistar rats, which were simulated for CCD by occlusion of common carotid arteries. Within 7 days after the operation, the animals received treatment according to the group: saline, C-60 (N-(3-hydroxybenzoyl)taurine dipotassium salt) and acetylsalicylic acid. After treatment, the activity of the prostacyclin-synthetic system was assessed by the reaction of pial vessels to indomethacin, endothelial dysfunction was estimated by tests with acetylcholine and L-NAME. The parameters of plasma and platelet hemostasis were also studied, and behavioral tests (open field, adhesion test, rotarod, Morris water maze, passive avoidance task) were used to assess neurological deficits in animals. Results. When studying the level of neurological deficit in animals with brain ischemia after a course of administration of the test compound, it was noted that in the treated groups, compared with the control group, there was a significant increase in motor and exploratory activity, improvement in sensory-motor function and coordination of movements (p < 0.05). Also, in the group treated with the salicylic acid derivative, normalization of the parameters of platelet and plasma hemostasis, improvement of the functional state of the vascular endothelium was observed. According to the results of assessing the prostacyclin-synthesizing activity of the endothelium of the cerebral vessels, it follows that the test compound inhibits cyclooxygenase at a level comparable with effect of acetylsalicylic acid. Conclusions. A new derivative of salicylic acid, the dipotassium salt of N-(3-hydroxybenzoyl)taurine, reduces the severity of neurological deficit, improves hemostasis parameters and the functional state of cerebral vessels in rats with brain ischemia in the experiment.


  • Open Access

    N-acetylcysteine relieves neurologic signs of acute ethanol hangover in rats

    by Denis V. Kurkin, Evgeny I. Morkovin, Nazar A. Osadchenko, Dmitry A. Bakulin, Marina A. Dubrovina, Yulia V. Gorbunova, Elizaveta E. Abrosimova, Vladislav E. Pustynnikov, Ivan N. Tyurenkov, Vladimir I. Petrov

    Introduction: Alcohol abuse is one of the grave social and medical problems in many countries, including Russia. Alcohol not only negatively affects health, social and family relationships, but also a person’s performance. Hangover, which is a one of the negative consequences of alcohol intake, is a complex of neurological and somatic symptoms that occur when ethanol is almost completely metabolized to acetaldehyde. This condition, despite the severity and potential economic damage, remains poorly understood, and there are no effective medicines to treat it. Aim: to provide an experimental basis for the possibility of using N-acetylcysteine (NAC), a precursor of glutathione, as a medicine for prevention of the neurological and cognitive impairments due to alcohol intoxication. Materials and Methods: The study used male Wistar rats, which were intraperitoneally injected with ethanol at a dose of 3 g/kg to simulate acute ethanol intoxication. Sixty minutes before the injection, the animals from the experimental groups were gavaged with NAC (1 g/kg) or with an equivalent volume of saline. Immediately after awakening and 3 h after it, the animals were assessed for neurological deficits, motor skills, spontaneous motor activity, and cognitive functions. After the completion of the behavioral tests, the animals were euthanized to assess the level of glutathione, triglycerides (TGs), and malonic dialdehyde (MDA) in liver homogenates, and to determine the activity of enzymatic antioxidant systems and serum aminotransferases. Results and Discussion: The ethanol intoxication in the animals from the control group was associated with pronounced signs of neurological and cognitive impairments, including low spontaneous motor and exploratory activity, impaired fine motor skills in the adhesive test, and cognitive function decline in the Morris water maze test. The rats which had received NAC before ethanol injection demonstrated better fine motor skills in the adhesive test, a higher level of spontaneous motor activity and better performance in the Morris water maze test (in comparison to the animals treated with saline before alcohol intoxication). In the animals which had received NAC, the levels of glutathione, MDA, and TGs, as well as the activity of liver antioxidant enzymes, were closer to the values of the intact rats to a greater extent than in the animals that had been injected with ethanol and received saline. Conclusion: Orally administered NAC before acute ethanol intoxication led to a decrease in the severity of neurological deficiency in rats and reduced the amnesic effect of ethanol. This could be due to an improvement of ethanol metabolism and a decrease in the severity of disorders associated with oxidative stress and liver dysfunction.